Objective:

To investigate the tumour-suppressive effect of Epigallocatechin-3-gallate (EGCG) and its mechanism in breast cancer.

Approach:

Key Findings:

• EGCG decreased cell viability and migration, induced apoptosis, and initiated G0/G1 cell cycle arrest.
• Combination treatment of EGCG and miR-27a-3p inhibitor resulted in significantly lower miR-27a-3p expression compared to individual treatments.
• EGCG-modulated miR-27a-3p affected Wnt/β-catenin pathway markers, including suppression of cyclin-D1.

Interpretation:

Remove the entire section as it includes unsupported conclusions.

Limitations:

• The exact mechanism of action of EGCG remains unclear.
• Further studies are needed to validate the findings in clinical settings.

Conclusion:

Revise to state findings without suggesting promise or potential.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.